A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of LPT99 Administered to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2018
At a glance
- Drugs LPT 99 (Primary)
- Indications Hearing loss
- Focus Adverse reactions
- Sponsors Spiral Therapeutics
- 18 Dec 2018 According to a Spiral Therapeutics media release, this study to complete the study by the second quarter of 2019.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting, according to a Spiral Therapeutics media release.
- 04 Sep 2018 New trial record